DocDollars

Biogen, Inc.

MA · United States · Reporting entity ID 100000000193

Total reported 2019–2025
$622.1M
#30 of 2,960 reporting companies — 0.7% of all reported industry payments
$97.3M in general payments across 282,093 records, plus $524.9M in research funding across 6,749 records.

How it breaks down

General payments $97,295,779
Research funding $524,853,137

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Biogen, Inc. reported $622.1M to US doctors and teaching hospitals from 2019 to 2025, ranking #30 of 2,960 reporting companies. 84% of that was research funding and 16% general payments such as consulting, speaking, food and travel. 282,093 general payment records and 6,749 research records were filed.

Common questions about Biogen, Inc.

How much has Biogen, Inc. paid US doctors?

Biogen, Inc. reported $622,148,915 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $97,295,779 in general payments, $524,853,137 in research funding.

How does Biogen, Inc. rank among drug and device companies?

It ranks #30 of 2,960 reporting entities by total reported value, about 0.7% of all industry payments in the dataset.

Does a payment from Biogen, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.